Mehrdad Shamloo
ASSOCIATE PROFESSOR
NEUROSURGERY
Canary Center at Stanford
United States of America
Biography
Mehrdad received his doctoral degree in 1999 from the Wallenberg Neuroscience Center of Lund University in Sweden. He was recruited to the San Francisco Bay Area the same year where he held several positions at biopharmaceutical companies, including Affymax and AGY Therapeutics, until 2008. During this time he was responsible for the discovery and development of novel neuroprotective and regenerative small molecule and peptide therapeutics for multiple diseases. As the program leader for neuroprotection and regeneration programs at AGY Therapeutics, his work enabled several patent applications, scientific publications, and an IND application and subsequent clinical trials.
Research Interest
normal and pathological brain function so that we can contribute to the discovery of novel therapeutic approaches for neurologic disorders such as stroke, Alzheimer’s disease (AD), and autism.
Publications
-
Simmons DA, Belichenko NP, Ford EC, Semaan S, Monbureau M, Aiyaswamy S, Holman CM, Condon C, Shamloo M, Massa SM, Longo FM. A small molecule p75NTR ligand normalizes signalling and reduces Huntington’s disease phenotypes in R6/2 and BACHD mice. Human molecular genetics. 2016 Nov 15;25(22):4920-38.
-
Huang WH, Guenthner CJ, Xu J, Nguyen T, Schwarz LA, Wilkinson AW, Gozani O, Chang HY, Shamloo M, Luo L. Molecular and neural functions of Rai1, the Causal Gene for Smith-Magenis syndrome. Neuron. 2016 Oct 19;92(2):392-406.
-
Yi B, Jahangir A, Evans AK, Briggs D, Ravina K, Ernest J, Farimani AB, Sun W, Rajadas J, Green M, Feinberg EN. Discovery of novel brain permeable and G protein-biased beta-1 adrenergic receptor partial agonists for the treatment of neurocognitive disorders. PloS one. 2017 Jul 26;12(7):e0180319.
